Compare MOVE & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOVE | PHAT |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | 32 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 894.0M |
| IPO Year | 2021 | 2019 |
| Metric | MOVE | PHAT |
|---|---|---|
| Price | $22.05 | $11.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | 61.6K | ★ 1.3M |
| Earning Date | 04-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | N/A | ★ N/A |
| Revenue | $433,000.00 | ★ $175,110,000.00 |
| Revenue This Year | $1,460.71 | $93.04 |
| Revenue Next Year | $96.77 | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $0.51 | $3.92 |
| 52 Week High | $34.87 | $18.31 |
| Indicator | MOVE | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 63.63 | 43.75 |
| Support Level | $6.77 | $11.04 |
| Resistance Level | $34.87 | $12.83 |
| Average True Range (ATR) | 2.75 | 0.73 |
| MACD | 0.79 | -0.13 |
| Stochastic Oscillator | 73.44 | 8.04 |
Corvex Inc is an AI cloud computing company that provides computing infrastructure for artificial intelligence workloads, including GPU-accelerated computing, confidential computing, and inference services. Its offerings are used by government and enterprise customers, including those with regulated workloads, to support the deployment and operation of AI models and data processing systems. The company generates revenue from the sale of Wellness Rings, portable chargers and charging cables, ring sizers, and mobile applications.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.